Francisco Flores, MD
Dermatology · Miramar, FLNPI 1114914934
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), consulting fees and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by LEO Pharma Inc. at 28.5% of the total. Among dermatology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 892 payments — averaging $31.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LEO Pharma Inc.$8K
- Johnson & Johnson$4K
- Dermavant Sciences, Inc.$3K
- AbbVie$3K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$2K
- Pfizer$1K
- plus $6K from 27 others
Across 685 payments — averaging $9717.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Taro Pharmaceuticals USA, Inc.$3.3M
- Takeda Pharmaceuticals U.S.A., Inc.$1.1M
- Sun Pharmaceutical Industries Inc.$802K
- Teva Pharmaceuticals USA, Inc.$520K
- Pfizer$406K
- Journey Medical Corporation$170K
- plus $348K from 7 others
What the payments were for
- Consulting fees$12,20244%
- Travel & lodging$130%
- Food & beverage$15,26255%
- Education$4812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LEO Pharma Inc. | 18 | $7,958 |
| Johnson & Johnson | 166 | $4,497 |
| Dermavant Sciences, Inc. | 87 | $2,757 |
| AbbVie | 133 | $2,627 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 54 | $2,363 |
| Pfizer | 117 | $1,365 |
| UCB, Inc. | 54 | $1,103 |
| Novartis | 47 | $953 |
| Regeneron Healthcare Solutions, Inc. | 29 | $587 |
| Incyte Corporation | 26 | $582 |
| Sanofi | 26 | $581 |
| Lilly USA, LLC | 27 | $559 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $350 |
| Amgen | 10 | $251 |
| Genentech USA, Inc. | 12 | $213 |
| Organon | 34 | $210 |
| Sun Pharmaceutical Industries Inc. | 7 | $142 |
| VYNE Pharmaceuticals Inc. | 6 | $140 |
| Organogenesis Inc. | 6 | $135 |
| Boehringer Ingelheim | 3 | $77 |
| Almirall LLC | 4 | $73 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $63 |
| Kyowa Kirin, Inc. | 3 | $63 |
| Arcutis Biotherapeutics, Inc. | 3 | $62 |
| Dermira, Inc. | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Mayne Pharma Commercial LLC | 4 | $37 |
| Encore Dermatology Inc. | 2 | $33 |
| Bristol Myers Squibb | 1 | $21 |
| Verrica Pharmaceuticals Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,957 in reported general payments places this provider in the 90th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 45 | $603,911 |
| Skyrizi PenRisankizumab-Rzaa | 26 | $530,810 |
| RinvoqUpadacitinib | 30 | $183,217 |
| OtezlaApremilast | 25 | $119,511 |
| OpzeluraRuxolitinib Phosphate | 31 | $63,402 |
| LitfuloRitlecitinib Tosylate | 11 | $43,248 |
| Dupixent PenDupilumab | 11 | $37,953 |
| OlumiantBaricitinib | 12 | $32,467 |
| Clobetasol Propionate | 318 | $15,575 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 442 | $13,609 |
| Triamcinolone Acetonide | 591 | $8,326 |
| Hydrocortisone | 360 | $7,409 |
| Fluocinolone Acetonide | 137 | $6,382 |
| Fluorouracil | 62 | $6,004 |
| Metronidazole | 74 | $5,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $4,497 | $603,91145 claims |
| AbbVieRinvoq | $2,627 | $183,21730 claims |
| AmgenOtezla | $251 | $119,51125 claims |
| Incyte CorporationOpzelura | $582 | $63,40231 claims |
| PfizerLitfulo | $1,365 | $43,24811 claims |
| Lilly USA, LLCOlumiant | $559 | $32,46712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Miramar
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
- Jeremy GreenCoral Gables$952K
- Mercedes GonzalezMiami$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.